Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial.
Park SJ, Ahn JM, Kang DY, Yun SC, Ahn YK, Kim WJ, Nam CW, Jeong JO, Chae IH, Shiomi H, Kao HL, Hahn JY, Her SH, Lee BK, Ahn TH, Chang KY, Chae JK, Smyth D, Mintz GS, Stone GW, Park DW; PREVENT Investigators.
Park SJ, et al.
Lancet. 2024 Apr 4:S0140-6736(24)00413-6. doi: 10.1016/S0140-6736(24)00413-6. Online ahead of print.
Lancet. 2024.
PMID: 38604213
This report is the principal analysis from the trial and includes all long-term analysed data. The trial is registered at ClinicalTrials.gov, NCT02316886, and is complete. ...
This report is the principal analysis from the trial and includes all long-term analysed data. The trial is registered at ClinicalTri …